HLX43 for injection is an innovative targeted PD-L1 antibody-drug conjugate (ADC) developed in collaboration between Henlius Biotech Co., Ltd. and Suzhou Yilian Biotechnology Co., Ltd. This drug is based on a fully humanized IgG1 anti-PD-L1 monoclonal antibody, conjugated with a novel tripeptide linker and a topoisomerase I inhibitor (derived from camptothecin compounds), forming a stable … Read more
Extracellular vesicles (EVs) are nanoparticle structures enveloped by phospholipids that are secreted by cells into the surrounding environment. Extracellular vesicles can convey various biomolecules that mediate intercellular communication and play a crucial role in physiological and pathological processes. Therefore, extracellular vesicles are emerging as new biomarkers, therapeutic targets, and drug delivery vehicles for various diseases. … Read more
When writing the previous article “TCE, Structure and Function, Bioassay Design,” I remained firmly in the “silent Fc” camp regarding TCE molecules. I wrote: For the new TCE molecules, it is generally preferred to choose a structural design with a silent Fc segment. By incorporating the Fc segment design, one can gain the advantage of … Read more
Click the blue text Follow us This issue Highlights of At the 2025 WCLC, Junshi Biosciences unveiled the groundbreaking phase I clinical data of its PD-L1 ADC (HLX43), attracting widespread attention in the industry. As the next frontier in the field of immune checkpoint inhibitors, PD-L1 ADC integrates the “dual strike” mechanism of immunotherapy and … Read more
The development of next-generation ADC drugs has gradually shifted towards the development of new toxins and linkers as foundational technologies. Multi-antibody or multi-toxin approaches have become a new trend. Following Araris and Puzhong’s advancements in tri-toxin and hexatozin,Aarvik has now introduced quadruple antibody-drug conjugates (ADCs). Aarvik may not have a prominent reputation in the ADC … Read more